F. Douglas Kling's most recent trade in NewAmsterdam Pharma Company NV was a trade of 51,043 Option (right to buy) done . Disclosure was reported to the exchange on July 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 51,043 | 162,702 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 15 Jul 2025 | 51,043 | 44,000 | - | 21.1 | 1,077,007 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 15 Jul 2025 | 51,043 | 95,043 | - | 10.9 | 556,369 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 15 Jul 2025 | 47,569 | 91,569 | - | 10.9 | 518,502 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 47,569 | 213,745 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 15 Jul 2025 | 44,025 | 47,544 | - | 21.4 | 941,255 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.12 per share. | 15 Jul 2025 | 3,544 | 44,000 | - | 22.1 | 78,393 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.19 per share. | 16 Jun 2025 | 81,891 | 62,109 | - | 19.2 | 1,571,488 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 78,101 | 372,829 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 16 Jun 2025 | 78,101 | 122,101 | - | 10 | 781,010 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 21,899 | 261,314 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 16 Jun 2025 | 21,899 | 144,000 | - | 10.9 | 238,699 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.75 per share. | 16 Jun 2025 | 18,109 | 44,000 | - | 19.8 | 357,653 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 100,000 | 450,930 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 15 May 2025 | 100,000 | 144,000 | - | 10 | 1,000,000 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 May 2025 | 100,000 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 15 Apr 2025 | 100,000 | 144,000 | - | 10 | 1,000,000 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 100,000 | 550,930 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Apr 2025 | 99,090 | 44,910 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Apr 2025 | 910 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 16,539 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 60,539 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Mar 2025 | 100,000 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 88,112 | 47,251 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 88,112 | 132,112 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 11,888 | 650,930 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 17 Mar 2025 | 11,888 | 144,000 | - | 10 | 118,880 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 90,782 | 135,363 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 90,782 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 90,782 | 134,782 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 9,218 | 126,145 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 9,218 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 9,218 | 53,218 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 56,863 | 100,863 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 56,863 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 56,863 | 239,723 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 13,578 | 226,145 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 13,578 | 57,578 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 8,914 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 4,664 | 52,914 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 104,174 | 321,971 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 104,174 | 148,174 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 80,359 | 67,815 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 25,385 | 296,586 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 25,385 | 69,385 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 23,815 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 20,237 | 49,148 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 5,148 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 44,000 | 44,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Douglas F. Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 250,000 | 250,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | F. Douglas Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 323,771 | 323,771 | - | - | Option (right to buy) |